Patents by Inventor Srikant Viswanadha

Srikant Viswanadha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Kinase modulators
    Patent number: 11858907
    Abstract: The present invention provides PI3K protein kinase modulators of Formula (I) wherein R, n, R1, R2, L1, Cy1 and Cy2 are as defined herein, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: January 2, 2024
    Assignee: RHIZEN PHARMACEUTICALS AG
    Inventors: Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Swaroop K. Vakkalanka
  • NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS
    Publication number: 20230234938
    Abstract: The present invention provides novel poly(ADP-ribose) polymerase (PARP) inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods for the treatment, prevention and/or amelioration of PARP mediated diseases or disorders using them. In particular, the compounds described herein are useful for the treatment of carcinoma of the breast, ovarian cancer, carcinoma of the liver, carcinoma of the lung, small cell lung cancer, esophageal cancer, gall bladder cancer, pancreatic cancer and stomach cancer.
    Type: Application
    Filed: April 23, 2021
    Publication date: July 27, 2023
    Inventors: Debnath BHUNIYA, Srikant VISWANADHA, Gayatri Swaroop MERIKAPUDI, Swaroop Kumar Venkata Satya VAKKALANKA
  • PURINE DERIVATIVES AS SIK-3 INHIBITORS
    Publication number: 20230167116
    Abstract: The present invention relates to novel inhibitors of salt-inducible kinase-3 (SIK3), methods of preparing them, pharmaceutical compositions containing them and methods for the treatment and/or prevention of kinase mediated diseases or disorders using them.
    Type: Application
    Filed: May 11, 2021
    Publication date: June 1, 2023
    Inventors: Prashant K. BHAVAR, Srikant VISWANADHA, SRIDHAR VEERARAGHAVAN, Babu GOVINDARAJULU, Swaroop Kumar Venkata Satya VAKKALANKA
  • COMPOSITIONS COMPRISING A DHODH INHIBITOR FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
    Publication number: 20220387362
    Abstract: The present invention relates to a method of treatment of acute myeloid leukemia (AML). In one embodiment, the present invention relates to a method of treating acute myeloid leukemia (AML) comprising administering to a subject in need thereof a dihydroorotate dehydrogenase (DHODH) inhibitor, alone in combination with at least one/ms-like tyrosine kinase 3 (FLT-3) inhibitor and/or a DNA polymerase inhibitor.
    Type: Application
    Filed: October 20, 2020
    Publication date: December 8, 2022
    Inventors: Srikant VISWANADHA, Swaroop Kumar Venkata Satya VAKKALANKA
  • Dual selective PI3 delta and gamma kinase inhibitors
    Patent number: 11466006
    Abstract: The present invention relates to dual delta (?) and gamma (?) PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of Pi3K kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: October 11, 2022
    Assignee: RHIZEN PHARMACEUTICALS AG
    Inventors: Swaroop K. Vakkalanka, Prashant K. Bhavar, Srikant Viswanadha, Govindarajulu Babu
  • COMPOSITIONS COMPRISING A CRAC INHIBITOR AND A CORTICOSTEROID AND METHODS OF USE THEREOF
    Publication number: 20220040162
    Abstract: The present disclosure relates to a method of treating an autoimmune, respiratory and/or inflammatory disease or condition (such as psoriasis, rheumatoid arthritis, asthma, or COPD) by administering at least one calcium release-activated calcium (CRAC) modulator (such as a CRAC inhibitor) and at least one corticosteroid.
    Type: Application
    Filed: September 13, 2019
    Publication date: February 10, 2022
    Inventors: Srikant Viswanadha, Swaroop Kumar Venkata Sat Vakkalanka
  • NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES
    Publication number: 20210401840
    Abstract: The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
    Type: Application
    Filed: April 15, 2021
    Publication date: December 30, 2021
    Inventors: Dhanapalan Nagarathnam, Swaroop K. Vakkalanka, Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Prashant K. Bhavar
  • NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES
    Publication number: 20210371416
    Abstract: The present invention provides compounds useful as c-Met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of c-Met kinase mediated disease or disorders with them.
    Type: Application
    Filed: May 30, 2021
    Publication date: December 2, 2021
    Inventors: Swaroop K. V. S. Vakkalanka, Dhanapalan Nagarathnam, Srikant Viswanadha, Meyyappan Muthuppalaniappan, Govindarajulu Babu, Prashant K. Bhavar
  • Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
    Patent number: 11065236
    Abstract: This present invention relates to a method of treating a autoimmune, respiratory and/or inflammatory disease or condition (e.g., psoriasis, rheumatoid arthritis, asthma, COPD). The method comprises administering a PI3K Delta inhibitor or a dual PI3K Delta-Gamma inhibitor and a PDE4 inhibitor. The present invention also relates to pharmaceutical compositions containing a PI3K Delta or dual PI3K Delta-Gamma inhibitor and a PDE4 inhibitor.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: July 20, 2021
    Assignee: Rhizen Pharmaceuticals SA
    Inventors: Swaroop K. Vakkalanka, Srikant Viswanadha
  • 3,5-disubstituted-3H-imidazo[4,5-b]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases
    Patent number: 11066402
    Abstract: The present invention provides compounds useful as c-Met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of c-Met kinase mediated disease or disorders with them.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: July 20, 2021
    Assignee: Rhizen Pharmaceuticals SA
    Inventors: Swaroop K. V. S. Vakkalanka, Dhanapalan Nagarathnam, Srikant Viswanadha, Meyyappan Muthuppalaniappan, Govindarajulu Babu, Prashant K. Bhavar
  • Intermediates useful in the synthesis of compounds as modulators of protein kinases
    Patent number: 11020399
    Abstract: The present invention provides compounds of formula (10), formula (12), formula (14) and formula (15) wherein R, R1, R2, Cy1 and X are as described herein.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: June 1, 2021
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Dhanapalan Nagarathnam, Swaroop K. Vakkalanka, Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Prashant K. Bhavar
  • NOVEL GLUTAMINASE INHIBITORS
    Publication number: 20210032236
    Abstract: The present disclosure provides compounds of formula (I) to (III) as glutaminase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders involving glutamine.
    Type: Application
    Filed: March 20, 2020
    Publication date: February 4, 2021
    Inventors: Prashant K Bhavar, Swaroop K. Vakkalanka, Srikant Viswanadha, Gayatri Swaroop Merikapudi, Govindarajulu Babu
  • METHOD OF TREATMENT AND COMPOSITIONS COMPRISING A DUAL P13K DELTA-GAMMA KINASE INHIBITOR AND A CORTICOSTEROID
    Publication number: 20210030757
    Abstract: This present disclosure relates to a method of treating autoimmune, respiratory and/or inflammatory diseases or conditions, e.g., asthma, COPD, rheumatoid arthritis and idiopathic pulmonary fibrosis (IPF). The method comprises administering a dual PI3K delta and gamma inhibitor and a corticosteroid. The present invention also relates to pharmaceutical compositions containing a dual PI3K delta and gamma inhibitor and a corticosteroid.
    Type: Application
    Filed: August 21, 2020
    Publication date: February 4, 2021
    Inventors: Swaroop K. V. S. Vakkalanka, Srikant Viswanadha
  • DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS
    Publication number: 20210032248
    Abstract: The present invention relates to dual delta (?) and gamma (?) PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of Pi3K kinase mediated diseases or disorders with them.
    Type: Application
    Filed: May 1, 2020
    Publication date: February 4, 2021
    Inventors: Swaroop K. Vakkalanka, Prashant K. Bhavar, Srikant Viswanadha, Govindarajulu Babu
  • Dual selective P13 delta and gamma kinase inhibitors
    Patent number: 10851107
    Abstract: The present invention relates to dual delta (?) and gamma (?) PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of Pi3K kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: December 1, 2020
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Swaroop K. Vakkalanka, Prashant K. Bhavar, Srikant Viswanadha, Govindarajulu Babu
  • Method of treatment and compositions comprising a dual PI3K delta-gamma kinase inhibitor and a corticosteroid
    Patent number: 10786504
    Abstract: This present disclosure relates to a method of treating autoimmune, respiratory and/or inflammatory diseases or conditions, e.g., asthma, COPD, rheumatoid arthritis and idiopathic Pulmonary Fibrosis (IPF). The method comprises administering a dual PI3K delta and gamma inhibitor and a corticosteroid. The present invention also relates to pharmaceutical compositions containing a dual PI3K delta and gamma inhibitor and a corticosteroid.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: September 29, 2020
    Assignee: Rhizen Pharmaceuticals SA
    Inventors: Swaroop K. V. S. Vakkalanka, Srikant Viswanadha
  • CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL MODULATORS FOR TREATING HEMATOLOGICAL AND SOLID CANCERS
    Publication number: 20200281918
    Abstract: The present invention relates to the use of a calcium release-activated calcium (CRAC) channel modulator, such as N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-(quinolin-6-yl)acetamide (Compound (A)) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing such a CRAC channel modulator for the treatment of haematological and solid cancers.
    Type: Application
    Filed: October 29, 2018
    Publication date: September 10, 2020
    Inventors: Srikant Viswanadha, Swaroop Kumar Kumar Venkata Sat Vekalanka
  • NOVEL KINASE MODULATORS
    Publication number: 20200239427
    Abstract: The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
    Type: Application
    Filed: August 30, 2019
    Publication date: July 30, 2020
    Inventors: Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Swaroop K. Vakkalanka
  • CRAC CHANNEL MODULATORS FOR TREATING ESOPHAGEAL CANCER
    Publication number: 20200237743
    Abstract: The present invention relates to the use of a calcium release-activated calcium (CRAC) channel modulator, such as N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-(quinolin-6-yl)acetamide (Compound (A)) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing such a CRAC channel modulator for the treatment of esophageal cancer.
    Type: Application
    Filed: October 16, 2018
    Publication date: July 30, 2020
    Inventors: Srikant Viswanadha, Swaroop Kumar Venkata Sataya Vakkalanka
  • PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A P13 DELTA OR DUAL P13 DELTA-GAMMA KINASE INHIBITOR
    Publication number: 20200237735
    Abstract: This present invention relates to a method of treating a autoimmune, respiratory and/or inflammatory disease or condition (e.g., psoriasis, rheumatoid arthritis, asthma, COPD). The method comprises administering a PI3K Delta inhibitor or a dual PI3K Delta-Gamma inhibitor and a PDE4 inhibitor. The present invention also relates to pharmaceutical compositions containing a PI3K Delta or dual PI3K Delta-Gamma inhibitor and a PDE4 inhibitor.
    Type: Application
    Filed: August 30, 2019
    Publication date: July 30, 2020
    Inventors: Swaroop K Vakkalanka, Srikant Viswanadha